^
Association details:
| Biomarker: | IGH mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | iFCG (cyclophosphamide + fludarabine IV + Gazyva (obinutuzumab) + Imbruvica (ibrutinib)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION
Published date:
05/12/2022
Excerpt:
The iFCG regimen, using only 3 cycles of chemotherapy (as opposed to 6 cycles of chemoimmunotherapy) achieves a very high rate of U-MRD in previously-untreated pts with CLL with IGHV-M CLL.
Trial ID:
Source:
Title:
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Published date:
05/18/2021
Excerpt:
The iFCG regimen with only 3 cycles of chemotherapy is an effective, time-limited regimen for patients with CLL with mutated IGHV and without del(17p)/TP53 mutation.
